SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Sartorius Stedim Biotech S.A. SRTOY OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • FR • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Sartorius Stedim Biotech S.A. (SRTOY) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $21.67. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $2.9B, -5.9%/yr average growth. Net income is $255M, growing at -20.8%/yr. Net profit margin is 9% (thin). Gross margin is 45.3% (-7.2 pp trend).

Balance sheet: total debt is $2.7B against $4.1B equity (Debt-to-Equity (D/E) ratio 0.67, moderate). Current ratio is 1.02 (adequate). Debt-to-assets is 34.3%. Total assets: $8.0B.

Analyst outlook: 0 / 1 analysts rate SRTOY as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 15/100 (Fail), Past 100/100 (Pass), Health 50/100 (Partial), Moat 64/100 (Partial), Future 20/100 (Fail), Income 45/100 (Partial).

SRTOY SharesGrow Score Overview

44/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 64/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SRTOY

SRTOY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

SRTOY: -5.9%/yr revenue is, -20.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

SRTOY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet SRTOY: Debt-to-Equity (D/E) ratio 0.67 (moderate), Current ratio is 1.02 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

SRTOY: Gross margin is 45.3% (-7.2 pp trend), $211B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 64/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate SRTOY as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

SRTOY: Net profit margin is 9%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range17.395-26.54

Volume8.51K

Avg Volume (30D)111.58K

Market Cap$210.8B

Beta (1Y)1.17

Dividend Yield$0.0451

Share Statistics

EPS (TTM)0.03

Shares Outstanding$9.73B

IPO Date2022-02-09

Employees9,961

CEORene Faber

Financial Highlights & Ratios

Revenue (TTM)$2.85B

Gross Profit$1.29B

EBITDA$832.88M

Net Income$255.12M

Operating Income$527.33M

Total Cash$425.92M

Total Debt$2.75B

Net Debt$2.32B

Total Assets$8.01B

Price / Earnings (P/E)833.5

Price / Sales (P/S)73.96

Analyst Forecast

Rating ConsensusHold

Analysts Covering1

Buy 0% Hold 100% Sell 0%

Company Info

CountryFR

ExchangeOther OTC

CurrencyUSD

ISINUS80386Y1010

Price Chart

SRTOY

Sartorius Stedim Biotech S.A. ↗ · Other OTC

Healthcare • Medical - Instruments & Supplies

17.40 52WK RANGE 26.54

People Also View

Becton, Dickinson and Company

West Pharmaceutical Services, Inc.

The Cooper Companies, Inc.

Baxter International Inc.

Teleflex Incorporated

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message